Journal of Clinical Oncology · 13 Nov 2026
Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Saurabh Zanwarh-index 18, Doris K. Hansen, Oren Pasvolsky, Carlyn Tan, Lauren C. Peres, Utkarsh Goel, Rakesh Popat, Aimaz Afrough, Sireesha Asoori, Masooma Rana, Mrugakshi Dave, Andrew Portuguese, Efstathios Kastritis, James A. Davis, Joaquin Martinez-Lopez, Douglas Sborov, Jana Mihalyova, Susan Bal, Murali Janakiram, Darren Pan, Leyla Shune, Christopher Ferreri, Noa Biran, Megan Herr, Ariel Grajales-Cruz, Jack Khouri, Andre De Menezes Silva Corraes, Omar Castaneda Puglianini, Emily C. Liang, Eli Zolotov, Tiffany Richards, Mahmoud Gaballa, Gliceida Galarza Fortuna, Kelley Julian, Kimberly Green, Aishwarya Sannareddy, Larry D. Anderson, Shahzad Raza, Danai Dima, Lekha Mikkilineni, Faiz Anwer, Shaji Kumar, Saad Usmani, Chiung-Yu Huang, Hira Mian, Surbhi Sidana, Krina Patel, Thomas Martin, Yi Lin, Luciano Costa, on behalf of the US Multiple Myeloma Immunotherapy Consortium, Melissa Alsina, Rachid Baz, Frederick L. Locke, Shebli Atrash, Cindy Varga, Peter Voorhees, Binod Dhakal, Hamza Hassan, Jeries Kort, Raffaela Cassano Cassano, Rahul Banerjee, Hossam M. Ali, Hitomi Hosoya, Christen Dillard, Lisa Lee, Amrita Krishnan
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Saurabh Zanwar has the highest h-index among the authors (18).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (36)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 16 more references
A free account opens the rest of the citing papers and references on every paper’s page.